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Brief summary: Comparing people with HIV (PWH) to matched people without HIV over a 20-year 
follow-up, we report an increased risk for composite cardiovascular disease, stroke, ischaemic heart 














Evidence on the risk of cardiovascular disease (CVD) and CVD risk factors in people 
with HIV (PWH) is limited. We aimed to identify the risk of composite CVD, individual 
CVD events and common risk factors. 
Methods: 
This was a nationwide population-based cohort study comparing adult (≥18y) PWH with HIV-
negative individuals matched on age, sex, ethnicity and location. The primary outcome was 
composite CVD comprising stroke, myocardial infarction (MI), peripheral vascular disease (PVD), 
ischaemic heart disease and heart failure. The secondary outcomes were individual CVD events, 
hypertension, diabetes, chronic kidney disease (CKD) and all-cause mortality. Cox proportional 
hazard regression models were used to examine the risk of each outcome.  
Results:  
We identified 9233 PWH and 35721 HIV-negative individuals. An increased risk was found for 
composite CVD (adjusted hazard ratio [aHR] 1.50, 95% CI 1.28-1.77), stroke (aHR 1.42, 95% CI 1.08-
1.86), ischaemic heart disease (aHR 1.55, 95% CI 1.24-1.94), hypertension (aHR 1.37, 95% CI 1.23-
1.53), type 2 diabetes (aHR 1.28, 95% CI 1.09-1.50), CKD (aHR 2.42, 95% CI 1.98-2.94) and all-cause 














PWH have a heightened risk for CVD and common CVD risk factors, reinforcing the importance for 
regular screening for such conditions.  
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The expansion of access to antiretroviral therapy (ART) has substantially reduced AIDS-related 
mortality [1]. Subsequently, non-AIDS-related causes of death in people with HIV (PWH) has 
increased, such as causes due to cardiovascular disease (CVD) [1]. Previous estimates suggest that 
PWH have a 2-fold risk for developing CVD compared to their HIV-negative counterparts; though, 
most studies were conducted over a decade ago [2]. CVD risk may have changed over the last 
decade due to better management of common CVD risk factors in PWH [3, 4], earlier initiation of 
ART [5] and reduced toxicity of ART [6]. Thus, evidence on the current overall risk of CVD is 
unknown.  
The relationship between CVD and HIV is complex and poorly understood [6]. Various HIV and non-
HIV mechanisms may contribute to PWH’s susceptibility of CVD and may lead to varying risks for 
individual CVD events [6]. Most studies that report the risk of CVD events in PWH were conducted in 
the US, where healthcare access and health-seeking behaviours differ from other countries, 
including the UK where healthcare is free. For instance, a 2019 US study that investigated the risk of 
multiple CVD events in PWH used data from a large insurance database thus excluding uninsured 
individuals who are more deprived and vulnerable to CVD [7]. Similarly, the Veterans Aging Cohort 
Study (VACS) has investigated various CVD events [8-10]; however, this cohort of US veterans 
represent a more deprived older population with a high proportion of people from ethnic minority 
groups (70-80%) and few women (4%), limiting the generalisability of their results [8, 9, 11]. Studies 
conducted outside the US often suffer from design limitations, such as not controlling for key 
confounders (e.g. ethnicity) [12-14] and not matching the comparison group [12, 14]. Additionally, 
most studies focus on stroke, myocardial infarction (MI) and heart failure, thus limiting the evidence 












Our primary aim is to identify the risk of composite CVD in PWH, comprising stroke, PVD, ischaemic 
heart disease, MI and heart failure. Second, we aim to identify the risk of individual CVD events, all-
cause mortality and common CVD risk factors including hypertension, type 2 diabetes and chronic 




We report our study following the Strengthening the Reporting of Observational Studies in 
Epidemiology guidelines for cohort studies [15]. Ethical approval was received by the Scientific 
Review Committee (reference number: 20SRC067). 
Study design  
We used a population-based matched cohort study design. The data was collected retrospectively; 
though, follow-up was done prospectively. Data was derived from The Health Improvement Network 
(THIN), a nationally representative UK-based anonymised database of primary care electronic 
records [16]. THIN data for diagnoses, lifestyle and anthropometric measurements have been 
considered well recorded and accurate [16, 17]. More than 90% of the UK population is registered 
with a general practice [18] and all general practices (n=808) available from THIN were included in 














All adults (≥18 years) with a first coded HIV diagnosis were eligible. The study entry began 12 months 
after registration with the general practice to ensure only incident outcome events of interest were 
captured; however, this may not have eliminated those with asymptomatic existing disease. The 
index date for PWH was the latest of the following: HIV diagnosis or one year after the registration 
date, the practice acceptable mortality recording date or the Vision IT system implementation date. 
Diagnoses before the study entry were considered prevalent HIV infections, and diagnoses after the 
study entry were considered incident HIV infections. 
For each person with HIV, up to four individuals without HIV were matched based on  region, sex, 
age within a one-year range and ethnicity. Criteria for matching was based on characteristics known 
to impact CVD risk in the general population [19]. Individuals without HIV were assigned the same 
index date as their matched counterpart.  
Outcomes  
The primary outcome of composite CVD included the first record of PVD, stroke, MI, ischaemic heart 
disease and heart failure; subsequent events were not considered. The individual CVDs were 
secondary outcomes along with all-cause mortality, hypertension, type 2 diabetes and CKD. CVD risk 
factors were chosen based on the literature and data availability. All conditions were identified by 
Read codes (supplementary table 1); Read codes were introduced in the UK National Health Service 
in 1985 and are checked for accuracy every 12 months [20]. All conditions were clinically diagnosed 














Follow up was from the index date until the exit date. Exit dates were calculated for each outcome 
of interest for each person and was the earliest date taken from the date of the outcome of interest, 
date they transferred out of the practice, date of death or study end date.  
Covariates  
Covariates were chosen based on existing literature regarding clinical importance and biological 
relevance and data availability [6]. Index year and age at index date were entered into all adjusted 
models as continuous variables. Sex (male and female), ethnicity (White, Black, Asian, Mixed race, 
and other), smoking status (current smoker, ex-smoker, and never smoked), body mass index (BMI) 
and social deprivation were entered as categorical covariates. BMI was defined as kg/m2 at study 
entry and classified using World Health Organization criteria as follows: underweight (BMI of <18·5 
kg/m2), normal weight (BMI of 18·5 kg/m2 to <25 kg/m2), overweight (BMI of 25 kg/m2 to <30 kg/m2) 
and obesity class I, II, and III were combined (BMI of ≥30 kg/m2) [21]. Townsend scores were used as 
a proxy for social deprivation; they are calculated based on employment, overcrowding (person per 
room in a household), car ownership and house ownership [22]. The 1st quintile of Townsend scores 
represent the least deprived individuals and the 5th quintile represents the most deprived 
individuals. Baseline data for hypertension, type 1 or 2 diabetes, CKD, PVD, stroke, MI, ischaemic 
heart disease and heart failure were also included as categorical covariates where appropriate. ART 
status, ART classification nor CD4 count data were available through THIN and therefore not 













Statistical methods  
All analyses were conducted in Stata 14.0 (College Station, Texas, USA). Descriptive statistics were 
used for reporting baseline data; presenting means for continuous variables and proportions for 
categorical variables. Cox proportional hazard regression models were used to calculate crude and 
adjusted hazard ratios (aHRs). A fitness test using Schoenfeld residuals methods identified three 
covariates that violated the proportional hazard assumption: age, ethnicity and smoking status. Due 
to the strong relationship between these covariates and CVD risk [23], they remained in the final 
model. Explorative models stratified by ethnicity and smoking status did not alter the final results. 
Each model included prevalent and incident HIV infections. Participants with CVD at baseline were 
excluded from the model investigating the risk of composite CVD; however, they were retained for 
outcomes of hypertension, diabetes, CKD and all-cause mortality. Similarly, participants with the 
outcome of interest at baseline were excluded for all other outcomes (e.g. those with stroke at 
baseline were excluded when investigating the risk for stroke). Subsequently, the baseline data 
relating to the outcome of interest was not entered as a covariate. Twenty multiple imputations by 
chained equations were used to impute missing data for BMI, smoking status, ethnicity and 
Townsend. A missing indicator was added to adjusted regressions for ethnicity due to the likeliness 
that missing was not at random [24]. 
Sensitivity analysis 
To assess for potential effects of bias caused by prevalent HIV infections, a sensitivity analysis was 
conducted among incident HIV infections only using Cox proportional hazard regression models 
adjusted the same as the main analysis. Due to a high proportion of missing data for ethnicity, a 
sensitivity analysis was conducted for the primary outcome with records of missing ethnicity data 














Sub-group analysis was undertaken for the following: age (<40 years old and ≥40 years old), sex 
(male and female), index year (2000 to 2009 and 2010 to 2019), smoking status (current or ex-
smoker and never smoked), deprivation level (least deprived and most deprived), ethnicity (White 
and non-White ethnic groups) and BMI (<30 kg/m2  and ≥30 kg/m2). Hazard ratios with 95% CIs are 
presented for each sub-group between people with and without HIV. Incident and prevalent 
infections were included. 




From January 2000 to January 2020, 9233 PWH and 36816 people without HIV were identified (table 
1). Age, sex and ethnicity were similar between the two groups by design: mean age was 41 years 
(standard deviation = 11), 34% were female, 37% were White, 22% were Black, 1% were Asian, 2% 
were of Mixed ethnicity, 2% were of other ethnicity and 36% were missing ethnicity data. Twenty-
three percent of PWH were in the most deprived quintile compared to 15% of people without HIV. 
Thirty-six percent of PWH and 46% of people without HIV were either overweight or obese. People 
without HIV had a higher proportion of people that reportedly never smoked (49% vs 55%), and 
PWH had a higher proportion of current smokers (30% vs 22%). The prevalence of PVD, stroke, MI, 
ischaemic heart disease, heart failure and CKD at baseline was higher in PWH whereas prevalence of 












A total of 890 CVD events occurred (176 PVD, 310 strokes, 242 MIs, 453 ischaemic heart disease, 190 
heart failures) during the study period (table 2). Incident rates for all primary and secondary 
outcomes were higher for PWH.  
Cardiovascular disease 
HIV infection was associated with an increased risk of CVD, with an HR of 1.50 (95% CI 1.28-1.77) 
after adjusting for age, sex, BMI, ethnicity, smoking status, deprivation, index year and baseline 
events for hypertension, diabetes and CKD (table 2). The risk remained when prevalent infections 
were removed (supplementary table 2) and when those without ethnicity data were removed from 
the model (data not shown). HIV infection was associated with an increased risk of stroke and 
ischaemic heart disease in all models, with a 42% (aHR 1.42, 95% CI 1.08-1.86) and 55% (aHR 1.55, 
95% CI 1.24-1.94) higher risk after adjustment, respectively. HIV infection was not associated with an 
increased risk for PVD, MI nor heart failure in any of the models (aHRs of 1.32 [95% CI 0.91-1.91]; 
1.30 [95% CI 0.94-1.79]; 1.32 [95% CI 0.92-1.89], respectively).  
Cardiovascular risk factors and all-cause mortality  
PWH had more than a 2-fold increased risk for CKD and all-cause mortality compared to people 
without HIV (aHRs of 2.42 [95% CI 1.98-2.94] and 2.84 [95% CI 2.48-3.25], respectively) (table 2). HIV 
infection was associated with both type 2 diabetes and hypertension (aHR of 1.28 [95% CI 1.09-1.50] 
and 1.37 [95% CI 1.23-1.53], respectively). In the sensitivity analysis, the risk of PWH developing CKD 
and all-cause mortality increased to a 3-fold risk and remained significant (supplementary table 2). 
The risk of type 2 diabetes was no longer significant; however, the risk for hypertension remained 














Adjusted hazard ratios for the sub group analyses are presented with 95% CIs in table 3 (composite 
and individual CVDs) and table 4 (CV risk factors and all-cause mortality). Here we present a 
summary of the findings.  
In both males and females, HIV infection was associated with an increased risk for composite CVD 
(47% and 60% respectively). Males with HIV had a 43% higher risk for stroke and a 47% higher risk 
for ischaemic heart disease whereas females had an 82% increased risk for ischaemic heart disease. 
Younger (<40y) and older (≥40) PWH had a 50% heightened risk for composite CVD compared to 
their uninfected counterparts. Older PWH (≥40y) had a 41% increased risk for stroke and 47% 
increased risk for ischaemic heart disease whereas younger (<40y) PWH had 2-times the risk for 
ischaemic heart disease and heart failure. Non-White PWH were not at a heighted risk for composite 
CVD, but had an 87% increased risk for stroke. White PWH had a 52% increased risk for composite 
CVD, and a 69% and 58% increased risk for MI and ischaemic heart disease, respectively. The 
association between HIV infection and CVD did not differ by deprivation status. No difference was 
found between obese individuals with and without HIV in the risk for composite or singular CVD. 
However, non-obese individuals with HIV were associated with a 53% increased risk of composite 
CVD, driven by a 62% increased risk for ischaemic heart disease. PWH that have never smoked or are 
current or ex-smokers had a 43% and 45% increased risk of composite CVD, and a 63% and 45% 
increased risk for ischaemic heart disease, respectively. HIV infection was associated with a 51% and 
49% increased risk for composite CVD in the earlier index years (2000-2009) and later years (2010-
2019), respectively. The earlier index years also resulted in a 68% heightened risk for ischaemic heart 
disease. 
In all sub-groups, PWH had a significantly higher risk of all-cause mortality and CKD. Compared to 
their uninfected counterparts, the following groups of PWH had an increased risk for type 2 












with an earlier index date (2000-2009). All groups, aside from the least deprived individuals and 





As the life expectancy of PLWH continues to increase, understanding their risk of age-related 
conditions is imperative for reducing excess morbidity and mortality. Our results demonstrate that 
PWH are at a heightened risk for CVD, particularly for stroke and ischaemic heart disease. We found 
no elevated risk for PVD, MI nor heart failure. We presented evidence on the risk of common CVD 
risk factors, highlighting an association between HIV infection and incident hypertension, type 2 
diabetes and CKD. Additionally, we reported a nearly 3-fold risk for all-cause mortality. The risk of 
individual CVD events and CVD risk factors varied across key demographics, including age, sex and 
ethnicity. 
Our study results are in line with previous evidence [2], confirming a sustained increased risk for 
composite CVD. This increased risk could be due to increased awareness of CVD in PWH and 
subsequently improved screening within this population. Another plausible cause is exposure to 
ART. ART has been found to decrease CVD risk by immune regulation and viral suppression; 
however, ART also increases the risk as a result of changes to lipid levels and metabolic profiles [6, 
25]. The relationship between ART and CVD is complex and long-term effects are unclear [6, 25, 26]. 
Whilst the current study was unable to control for ART, the risk remained the same in earlier (2000-
2009) and later (2010-2019) index years. Initiation of ART has increased to 90% in the UK over the 
last decade [27], though this sub-group analysis indicates that CVD risk may not be impacted by 












impact of ART on CVD risk. Other key confounders such as age and smoking did not impact the risk 
of CVD in our study. The increased risk we report may therefore be due to other HIV-related 
mechanisms such as persistent immune activation and inflammation caused from the presence of 
HIV viraemia and microbial translocation which occurs regardless of treatment status [28].  
In accordance to other studies, we found an increased risk for stroke. However, our findings indicate 
a lower risk than the 2-fold risk reported in a 2018 meta-analysis, which is likely inflated due to the 
high-risk populations reviewed [2]. Two separate studies reported a 2- and 3-fold risk for stroke [7, 
30]; however, ethnicity was not controlled for which is a known confounder. Three studies that were 
powered and matched by age, sex and ethnicity reported significant effect sizes in line with ours 
(HRs of 1.93, 1.17, and 1.21), despite being carried out in the US and not being population-based [9, 
31, 32]. We reported a 55% increased risk for ischaemic heart disease; though, there was no risk for 
MI. This could be due to a lack of power as the overall effect size was still large (30%) along with 
many of the sub-groups for this outcome (i.e. females). Two 2019 meta-analyses report a 73 to 96% 
increased risk for MI in PWH [33, 34]. To our knowledge, no study has investigated the relative risk 
of incident ischaemic heart disease, indicating the need for future studies to confirm these 
important findings and examine the role MI plays within this risk. 
Inconsistent with other studies investigating heart failure, we found no increased risk for this 
outcome. The two most recent studies (2019 and 2018) found more than a 2-fold risk [7, 35], a 
finding we reported only in younger (<40y) PWH. Similar to MI, the insignificant finding for heart 
failure could be due to a lack of power as the effect size was large (32%). The same is true for PVD 
(32%). None of the sub-groups were at an increased risk for PVD; however, a downward trend in risk 
is indicative when comparing the later (2010-2019) and earlier index years (2000-2009). Evidence on 
PVD risk is limited and inconclusive [6]. A VACS study found a 19% increased risk in PVD [8] whereas 
two other large studies [7, 14] reported no increased risk. Further research is needed to understand 












We confirmed that people with HIV are at a heightened risk for hypertension, type 2 diabetes, CKD 
and all-cause mortality. Nearly all sub-groups were at twice the risk for CKD; however, those younger 
than 40 had 4-times the risk and the risk was 3-fold in the later index years (2010-2019). Similarly, 
those younger than 40 and those with a later index year (2010-2019) were at a 6-times and 3-times 
risk for all-cause mortality, respectively. Additionally, the least deprived PWH had a 4-fold risk of all-
cause mortality. These are important findings for understanding who should be prioritised in future 
research and targeted in prevention programmes. Despite hypertension, type 2 diabetes and CKD 
having minimal impact on the risk of CVD in our study, it is clear that screening of such CVD risk 
factors should be a priority. Annual screening for common CVD risk factors is recommended by the 
British HIV Association [36]. However, compared to other European studies [37, 38], the incidence 
for risk factors in the current study are lower which may indicate underdiagnosis of important CVD 
risk factors in PWH in the UK. Guidelines also advise for an annual CVD risk assessment for those 
older than 40 or if they have significant CVD risk factors [36]. However, the CVD risk assessment tool 
used in the UK (QRISK) has not been validated in PWH, and likely underestimates their true risk [36]. 
From our findings, we know PWH are at high risk for CVD, irrespective of their sex, age and smoking 
status. Therefore, regardless of CVD status and risk score, annual screening for CV risk factors and 
disease should be considered and trialled in future studies. 
The large population-based matched cohort used for our study is a notable strength. This allowed us 
to look at composite CVD, individual CVD events, common risk factors, the risk of each across key 
sub-groups and compare the risk to an HIV-negative population. Few studies have reported the risk 
of composite CVD and many suffer from design limitations; therefore, our robust study enhances the 
current evidence on the risk of CVD in PWH. Though, there are some limitations to mention. One key 
limitation is the absence of data relating to treatment status, ART regimens used, duration of 
treatment and CD4 T-cell counts, all of which have been shown to impact the risk of CVD [6]. This 
lack of data limits the interpretations possible from our findings. Further to this, some effect sizes 












found insignificant, which may indicate a lack of power for some of the outcomes. These results 
should therefore be interpreted with caution. Uncontrolled confounding is likely to remain, despite 
matching and adjusting for important covariates.   
In conclusion, PWH remain at a heightened risk for CVD, specifically stroke and ischaemic heart 
disease. An elevated risk was also found for hypertension, type 2 diabetes, CKD and all-cause 
mortality. These risks differed across key demographics such as age, sex and ethnicity; indicating 
who to target in future research and prevention strategies. Our results reiterate the importance of 
regular screening for CV risk factors and disease in PWH. However, common CVD risk factors had 
little impact on the overall risk of CVD, hence, an HIV-validated risk assessment tool and further 
investigation into who should receive regular assessments would be beneficial. Additional research 
is needed to ascertain the mechanisms behind the risk of individual CVD events. A better 
understanding of contributing factors could aid in reducing the excess morbidity and mortality 
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Table 1. Baseline demographics; figures are N (%) unless otherwise stated. 
 People with HIV 
(n=9233) 
People without HIV 
(n=36816) 
Age at index date   
Mean (standard deviation) 41.0 (11.0) 41.0 (11.0) 
Sex   
Female 3172 (34.4) 12598 (34.2) 
Ethnicity    
White 3424 (37.1) 13695 (37.2) 
Black 2080 (22.5) 8243 (22.4) 
Asian 89 (1.0) 352 (1.0) 
Mixed 153 (1.7) 611 (1.7) 
Other 174 (1.9) 667 (1.8) 
Missing 3313 (35.9) 13248 (36.0) 
Townsend / deprivation quintile   
1st quintile (least deprived) 700 (7.6) 5564 (15.1) 
2nd quintile 880 (9.5) 5262 (14.3) 
3rd quintile 1312 (14.2) 6347 (17.2) 
4th quintile 1740 (18.9) 6325 (17.2) 
5th quintile (most deprived) 2155 (23.3) 5649 (15.3) 
Missing 2446 (26.5) 7669 (20.8) 
Body mass index    
Underweight (<18.5 kg/m2) 307 (3.3) 614 (1.7) 
Normal weight (18.5 kg/m2 to <25 kg/m2) 3567 (38.6) 11317 (30.7) 
Overweight (25 kg/m2 to <30 kg/m2) 2143 (23.2) 10146 (27.6) 
Obese (≥30 kg/m2) 1152 (12.5) 6726 (18.3) 
Missing 2064 (22.4) 8013 (21.8) 
Smoking status   
Current smoker 2750 (29.8) 8132 (22.1) 












Never smoked 4499 (48.7) 20390 (55.4) 
Missing 692 (7.5) 2838 (7.7) 
Comorbidities   
Composite CVDa 353 (3.8) 939 (2.6) 
Peripheral vascular disease 48 (0.5) 143 (0.4) 
Stroke 152 (1.7) 311 (0.8) 
Myocardial infarction  102 (1.1) 243 (0.7) 
Ischemic heart disease 174 (1.9) 541 (1.5) 
Heart failure 49 (0.5) 99 (0.3) 
Hypertension 713 (7.7) 3200 (8.7) 
Diabetes (type 1 and type 2) 307 (3.3) 1257 (3.4) 
Chronic kidney disease 98 (1.1) 258 (0.7) 
a Composite cardiovascular disease (CVD) comprises peripheral vascular disease, stroke, myocardial infarction, 




























 per 1000 person-years 
Person years 































































































1.49 (1.27, 1.74) ** 
1.50 (1.28, 1.77) ** 









1.37 (0.96, 1.95)  










1.47 (1.13, 1.92) ** 











1.29 (0.95, 1.76)  
1.30 (0.94, 1.79) 
Ischaem









1.52 (1.22, 1.89) ** 











1.36 (0.96, 1.91)  











1.30 (1.17, 1.44) ** 
1.37 (1.23, 1.53) ** 
T









1.09 (0.93, 1.27)  
1.28 (1.09, 1.50) ** 













2.32 (1.92, 2.80) ** 












3.25 (2.85, 3.70) ** 
2.84 (2.48, 3.25) ** 
a The num
ber of participants w
ill differ for each outcom
e. This is due to the exclusion of participants that already had the outcom
e at baseline. 
b Percentages correspond w
ith the num
ber of events (num
erator) and the num
ber of individuals for that particular group (denom
inator) w
ithin the corresponding row
. 
c A
djusted for age, body m
ass index, sex, sm
oking status, ethnicity, deprivation, index year and events at baseline. 
d C
om




prises peripheral vascular disease, stroke, m
yocardial infarction, ischaem
ic heart disease and heart failure events. 
* P-value <0.05. 
** P-value <0.01. 
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 Table 3. Sub group analysis a for com
posite and individual CV
D







































1.47 (1.22, 1.76) ** 
1.36 (0.91, 2.03) 
1.43 (1.04, 1.97) *  
1.19 (0.84, 1.70) 
1.47 (1.15, 1.89) ** 
1.19 (0.78, 1.81) 
Fem
ale 
1.60 (1.12, 2.29) * 
1.02 (0.36, 2.90) 
1.49 (0.85, 2.61) 
2.15 (0.96, 4.80)  
1.82 (1.04, 3.20) * 









<40 years old 
1.50 (1.01, 2.24) * 
0.37 (0.05, 2.87) 
1.40 (0.73, 2.71) 
1.64 (0.76, 3.54)  
2.08 (1.15, 3.77) * 
2.42 (1.12, 5.22) * 
≥ 40 years old 
1.50 (1.26, 1.79) ** 
1.41 (0.96, 2.06) 
1.41 (1.04, 1.91) *  
1.23 (0.86, 1.75) 
1.47 (1.15, 1.88) ** 













1.34 (0.89, 2.02) 
1.07 (0.18, 6.21) 
1.87 (1.05, 3.36) *  
0.76 (0.25, 2.27) 
1.25 (0.65, 2.41) 
1.12 (0.51, 2.44) 
W
hite 
1.52 (1.20, 1.94) ** 
1.34 (0.77, 2.32) 
1.23 (0.81, 1.87) 
1.69 (1.07, 2.67) * 
1.58 (1.13, 2.23) ** 











1.24 (0.86, 1.79) 
1.13 (0.50, 2.55) 
1.38 (0.77, 2.46) 
1.43 (0.67, 3.02) 
1.44 (0.84, 2.45) 
0.88 (0.42, 1.85)  
L
east deprived 
1.25 (0.74, 2.10) 
0.87 (0.24, 3.17) 
1.40 (0.58, 3.38)  
1.67 (0.68, 4.10) 
1.28 (0.62, 2.64) 












1.30 (0.88, 1.92) 
1.28 (0.55, 3.01) 
1.65 (0.88, 3.09) 
0.77 (0.31, 1.96) 
1.35 (0.79, 2.31) 




1.53 (1.25, 1.88) ** 
1.34 (0.84, 2.15) 
1.36 (0.95, 1.95) 
1.38 (0.94, 2.03) 
1.62 (1.24, 2.13) ** 
1.32 (0.81, 2.15) 















1.45 (1.16, 1.80) ** 
1.11 (0.71, 1.75) 
1.36 (0.92, 2.00)  
1.27 (0.85, 1.90) 
1.45 (1.08, 1.96) *  




1.43 (1.09, 1.88) * 
1.74 (0.80, 3.81)  
1.38 (0.89, 2.13) 
1.39 (0.76, 2.54) 
1.63 (1.11, 2.40) *  









1.51 (1.24, 1.86) ** 
1.51 (0.96, 2.38) 
1.35 (0.96, 1.91) 
1.28 (0.85, 1.92) 
1.68 (1.28, 2.21) ** 
1.21 (0.75, 1.96) 
2010-2019 
1.49 (1.14, 1.95) ** 
0.96 (0.50, 1.87) 
1.58 (1.00, 2.50)  
1.32 (0.76, 2.24) 
1.32 (0.88, 1.97) 
1.41 (0.82, 2.42) 
a A
djusted for age, body m
ass index, sex, sm
oking status, ethnicity, deprivation, index year and events at baseline. 
b C
om




prises peripheral vascular disease, stroke, m
yocardial infarction, ischaem
ic heart disease and heart failure events. 
c N
on-W
hite sub-group includes people that identify as B
lack, A
sian, M
ixed or other. 
* P-value <0.05. 
** P-value <0.01. 
 
Downloaded from https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiab420/6356062 by guest on 09 November 2021
 
29 
 Table 4. Sub group analysis a for CV
D
 risk factors and all-cause m
















ype 2 diabetes 
C











1.42 (1.25, 1.61) ** 
1.33 (1.09, 1.61) **  
2.60 (2.03, 3.32) ** 
2.88 (2.46, 3.37) ** 
Fem
ale 
1.28 (1.05, 1.56) * 
1.13 (0.85, 1.51) 
2.10 (1.50, 2.95) ** 








1.57 (1.27, 1.93) ** 
1.22 (0.85, 1.76) 
4.67 (2.54, 8.58) ** 
6.73 (4.91, 9.21) ** 
≥ 40 years 
1.34 (1.18, 1.52) ** 
1.29 (1.08, 1.54) ** 
2.28 (1.84, 2.81) ** 











1.37 (1.22, 1.66) ** 
1.23 (0.94, 1.61) 
1.56 (1.04, 2.36) *  
3.44 (2.35, 5.03) ** 
W
hite 
1.28 (1.07, 1.52) ** 
1.16 (0.87, 1.53) 
2.88 (2.09, 3.98) ** 









1.32 (1.05, 1.66) * 
1.27 (0.92, 1.76) 
1.71 (1.07, 2.72) * 
2.45 (1.85, 3.23) ** 
L
east deprived 
1.11 (0.76, 1.62) 
1.72 (1.04, 2.87) *  
2.29 (1.29, 4.04) ** 










1.10 (0.87, 1.39) 
1.03 (0.79, 1.35) 
2.17 (1.42, 3.30) ** 




1.38 (1.20, 1.59) ** 
1.46 (1.16, 1.85) **  
2.33 (1.81, 3.00) ** 














1.19 (1.00, 1.42) * 
1.27 (0.99, 1.63) 
2.77 (2.05, 3.76) ** 




1.54 (1.33, 1.78) ** 
1.32 (1.06, 1.65) * 
2.17 (1.64, 2.88) ** 







1.34 (1.17, 1.53) ** 
1.40 (1.14, 1.71) ** 
2.08 (1.63, 2.65) ** 
2.75 (2.33, 3.25) ** 
2010-2019 
1.45 (1.21, 1.75) ** 
1.09 (0.84, 1.42) 
3.35 (2.37, 4.74) ** 
3.01 (2.37, 3.82) ** 
a Incident H
IV
 infections only, adjusted for age, body m
ass index, sex, sm
oking status, ethnicity, deprivation, index year and all outcom
es of interest at baseline. 
b N
on-W
hite sub-group includes people that identify as B
lack, A
sian, M
ixed or other. 
* P-value <0.05. 
** P-value <0.01. 
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